Citicoline eye drops 2% not checked

Omikron Italia S.r.l.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Glaucoma, Open-Angle
Main trialPhase 3
“To evaluate the efficacy of citicoline eye drops 2% in reducing visual field deterioration in patients with progressing OAG treated according to best clinical practice. Secondary objectives are assessing the effect of citicoline eye drops 2% on changes in structural parameters measured by Spectral Domain Optical Coherence Tomography (SD-OCT) and evaluating the safety of citicoline eye drops 2%”In the company’s words, NCT05710198 on ClinicalTrials.gov

Other drugs for Glaucoma, Open-Angle

All 16 drugs for Glaucoma, Open-Angle

Coming up1

Changes2

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 1 Jul 2029 Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Citicoline eye drops 2%

Following is part of Solo: you see every change to Citicoline eye drops 2% the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in